BioSpace News Archive

Drug Development

Outclassed by Eliquis, Bayer Halts Atrial Fibrillation Study of Factor XIa Inhibitor

Bayer’s investigational factor XIa inhibitor asundexian was inferior to BMS’ and Pfizer’s blockbuster blood thinner Eliquis (apixaban) in the Phase III OCEANIC-AF study.

November 20, 2023
·
2 min read
·
Tristan Manalac
NHS, Pharma Deal Doubles Annual Growth and Earmarks £400M for R&D

The new five-year deal will save the U.K.’s National Health Service an estimated £14 billion ($17.4 billion) and double the annual allowed growth in sales of branded medicines from 2% to 4% per year by 2027.

November 20, 2023
·
2 min read
·
Connor Lynch
Deals

Playing in the Hot Obesity Market, Carmot Braves Chilly IPO Waters

Armed with a pipeline of obesity and diabetes hopefuls, Carmot Therapeutics joins the small group of biotechs to attempt a Nasdaq debut this year.

November 20, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Next-Generation ADCs Strive to Overcome Toxicities, Payload Problems

As companies clamor for a piece of the antibody-drug conjugate pie, experts pose the question: is it possible to replicate the success of Enhertu?

November 20, 2023
·
5 min read
·
Hayley Shasteen
Drug Development

With New Phase III Data in Hand, Servier Eyes FDA Filing for Glioma Candidate

Vorasidenib decreased tumor volume by a mean of 2.5% every six months, compared to growth of 13.9% for placebo over the same time span. The candidate is also being tested in a regimen with Keytruda.

November 20, 2023
·
2 min read
·
Tristan Manalac
From the Bench to the Office: Advice for Graduate Students Considering Leaving Academia

A biopharma communications professional offers advice he wishes he’d received as a PhD student considering a career in industry.

November 20, 2023
·
11 min read
·
Ignacio Guerrero-Ros
Biologics Projected to Keep Gaining Ground in Cancer Therapeutics Market

The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.

November 20, 2023
·
4 min read
·
Patience Asanga
Find Therapeutics to Participate in Fireside Chat at the BTIG Ophthalmology Conference

Find Therapeutics Inc. announced that Philippe Douville, Find’s Chief Executive Officer and Robert Glanzman, Find’s Chief Medical Officer will participate in a fireside chat at the BTIG Ophthalmology Conference on Monday, November 27, 2023 at 11:00 a.m. EDT.

November 20, 2023
·
1 min read
Genetown

New Capital Strengthens ProtaGene’s Advanced Analytical Leadership in the Biologics and Cell and Gene Therapy Markets

ProtaGene, a leading global contract research organization dedicated to advanced analytics for biologics and cell and gene therapies, announced additional investment from Ampersand Capital Partners.

November 20, 2023
·
3 min read
BioMidwest

Halia Therapeutics to Present at the 5th Inflammasome Therapeutics Summit

Halia Therapeutics announced that David Bearss, Ph.D., President and Chief Executive Officer of Halia, will be participating in a panel discussion and presenting new data at the 5th Inflammasome Therapeutics Summit taking place on November 28 – 30, in Boston, MA.

November 20, 2023
·
3 min read